ERBB2 and breast carcinoma: Thus, lipogenic enzyme inhibitors, modulators of PPARγ transcriptional activity, and, perhaps, dietary omega-3 polyunsaturated FAs (e.g., DHA) may provide novel therapeutic strategies for the clinical management of HER2-positive breast carcinomas and may increase the efficacy of standard therapies [2, 20, 21].